BioNTech’s Oncology Ambition Collides With Labor Fury Ahead of Key Data Drop
23.05.2026 - 20:12:31 | boerse-global.de
As Chicago prepares to host the world’s largest cancer conference, BioNTech finds itself fighting on two fronts. On the clinical side, the Mainz-based biotech is about to lay out its strongest case yet that its pipeline can replace the fading Covid vaccine franchise. On the home front, it faces a blistering backlash from Germany’s third-largest union over a restructuring that will shed nearly one in five jobs.
The American Society of Clinical Oncology (ASCO) meeting, running from 29 May to 2 June, will see BioNTech present interim data from the pivotal ROSETTA-Lung-02 study. The trial is testing pumitamig, a bispecific PD-L1xVEGF-A antibody developed with Bristol Myers Squibb, combined with chemotherapy as a first-line treatment for non-small cell lung cancer. The company describes this as the third global dataset to show encouraging anti-tumor activity in that setting, and the readout feeds directly into the ongoing phase 3 registration program.
Gotistobart, a CTLA-4 inhibitor, will also take centre stage. BioNTech plans to unveil phase 2 overall survival data in patients with platinum-resistant ovarian cancer, a notoriously difficult-to-treat population. Early signs point to durable responses and a manageable safety profile, offering hope of a chemotherapy-free option for heavily pretreated women. Beyond these two core programs, the company will showcase multiple antibody-drug conjugates across various studies, underscoring a pipeline that now spans more than 25 phase 2 and phase 3 trials, 13 of which are registration-enabling.
Yet the scientific narrative is unfolding against a stark operational backdrop. In April, BioNTech announced it would cut roughly 1,860 positions — 22% of its workforce — and shut down production sites in Germany and Singapore as it halts all Covid vaccine manufacturing. First-quarter revenue fell to just €118.1 million, while the net loss widened to €531.9 million. Covid-related sales continue to slide in both Europe and the United States.
Should investors sell immediately? Or is it worth buying BioNTech?
The IGBCE, Germany’s third-largest trade union, has condemned the cuts as “social irresponsibility,” accusing management of sacrificing production capacity for short-term financial gain and damaging the country’s pharma and biotech ecosystem. The company, however, maintains its full-year revenue forecast of €2.0 billion to €2.3 billion and has launched a billion-euro share buyback program, signaling confidence that its oncology pivot will eventually pay off.
BioNTech’s goal is to transform into a multi-product oncology company by 2030, and the ASCO data represent a critical validation step. The company expects to file its first oncology regulatory applications this year and plans to report results from six advanced-stage studies in the coming months. But the market remains unconvinced. The stock closed Friday at €79.50, up 1.53% on the day but still down 15.25% over the past month and 8% below its 200-day moving average.
Analyst opinions reflect the uncertainty. J.P. Morgan rates the shares a Hold. Canaccord still recommends Buy but trimmed its price target from $171 to $158. Morgan Stanley, which rates the stock Overweight, nudged its target slightly higher to $126. The average Street view suggests upside, but the near-term trajectory hinges on whether the ASCO readouts can convince investors that pumitamig and gotistobart are more than clinical curiosities.
BioNTech at a turning point? This analysis reveals what investors need to know now.
For BioNTech, the week ahead is a dual test of credibility. It must show that its pipeline can deliver drugs that compete in oncology’s most crowded indications — while simultaneously managing the fallout from a painful restructuring that has already drawn sharp criticism from labor leaders. The scientific data from Chicago will set the tone, but the broader question of whether the company can execute its strategic pivot without alienating its workforce remains wide open.
Ad
BioNTech Stock: New Analysis - 23 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
